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Osteoarthritis (OA) is a heterogeneous condition in that a variety
of causes result in a common pathogenesis. This involves not only
articular cartilage, but the whole joint including subchondral bone,
ligaments, muscles, menisci, synovium, the capsule and joint ﬂuid.
Primary, or so-called idiopathic, OA is slowly progressing and is the
most common form of OA and increases in prevalence and severity
as humans and animals age. Often OA develops from a focal lesion,
which can be generated traumatically in animals and humans. Post-ttee of The Canadian Arthritis
l Models of Osteoarthritis,
Robin Poole, Department of
nada. Tel: 1-613-347-7673;
York, N.Y., USA.
s Research Society International. Ptraumatic OA may develop more rapidly and can be reproduced by
mechanical insult and surgically by creating joint instability.
The analysis of animal models of OA traditionally depends on
histological assessment of articular cartilage. But there are many
other important analyses that are used in characterizing human
disease including imaging, biomarkers and symptomatic
measurements. Although there are no DMOADs (disease-modifying
osteoarthritis drugs) currently available for human use, there are
drugs that have been shown to be disease modifying in animals
such as diacerhein, matrix metalloproteinase inhibitors, an
IL-1-convertase inhibitor, a cathepsin-K inhibitor, and salmon
calcitonin.
This conference was held to reach a better understanding and
a consensus of how best we can monitor and treat OA in
a preclinical setting. Many experts described the principal models
presently in use to reproduce OA experimentally. They have been
described in detail and debated as to which are appropriate and for
what and how should they be analyzed. These discussions and
presentations have been summarized and in most cases areublished by Elsevier Ltd. All rights reserved.
Recommended minimal ages of animals to enter OA studies (skeletal maturity)
based on the consensus of the breakout group participants
Species Age
Mice 10 weeks
Rats 3 months
Guinea pigs 6 months
Rabbits 8e9 months
Sheep 2 years
Goats 2 years
Horses 2 years
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Network ofﬁce at 1-416-586-4770 or can@arthritisnetwork.ca. The
discussions in the breakout sessions of this conference have also
been recorded and edited for clarity and are also included in this
web presentation.
In this paper, as in our discussions at the conference, we have
always been guided by reference to the human disease. This is
because our studies of experimental and natural OA in animals
must be conducted in such a fashion that they meaningfully guide
us in our understanding and treatment of human OA, as well as in
the veterinary care of animals. It is obvious that, wherever possible,
common tools and technologies should be used in preclinical and
clinical investigations.
We have attempted to summarize our discussions, although
these were often inconclusive as a result of diverse opinions from
over 160 participants. Hence, this is a guidance document repre-
senting work(s) in progress. It is not intended to provide deﬁnitive
direction since there exists differences of opinion. But there was
often a welcome general agreement on many aspects of this chal-
lenging research. We sincerely hope that our colleagues will ﬁnd
this document, and the collective information originating from this
rare meeting of the minds in this challenging ﬁeld, of value in
determining how to better care for this all too common debilitating
condition, which creates so much suffering in humans and animals.
Here we present what we feel is a reasonable consensus of the
participants’ views.Animal models
Animal models and human OA
Much more work on human OA is essential to understand
animal models better: the opposite also applies. Hence, preclinical
and clinical studies can and should be conducted in parallel. There
are many animal models that reproduce key aspects of human OA
in terms of natural history, mechanisms, signs and symptoms. Yet,
as not one animal model completely reproduces the signs and
symptoms of human OA, we must remain mindful to use the most
appropriate model to answer our scientiﬁc questions. Nevertheless,
animal models are essential for addressing safety and efﬁcacy of
various drugs and therapies because, at present, we lack human
therapeutic interventions that are structurally modifying and are
known to effectively control pain and symptoms. Symptomatic
aspects of human OA must, in future, be well characterized in
animal models.
Conference presentations conﬁrmed that many good animal
models of OA exist, but also revealed that we must be more critical
as to what they tell us. In particular, there appear to be opportu-
nities and a mandate to develop new models to better model the
patient’s clinical experience. Here we need input from patients/
consumers to help us examine, for example, structure/symptom
relationships in our models. Biomechanical studies are also
essential since the complex structures of joint tissues, such as
articular cartilage, determine the special mechanical properties and
hence functions of these tissues. The functional biomechanical
properties of a tissue, therefore, best reﬂect the complexity of
fundamental structural changes.
The genetic components of human OA are difﬁcult to model at
present since information is limited. Genetic differences may
manifest not just structurally but also behaviourally. Remember
that genetics is a research tool. One of the most promising appli-
cations of these tools and principles is in genomic breeding studies
of dogs predisposed and resistant to developing arthritis secondary
to congenital hip dysplasia1.Concerning the use of animals and those in veterinary practice
we should always remember that animals are stakeholders and not
just research tools. End points used in clinical veterinary practice
may help us when evaluating success of human therapeutic trials.
Some of the treatments/surgeries used in veterinary practice
replicate the human situation. The Food and Drug Administration
may wish to consider developing an OA guidance document for
both human and veterinary medicine.Ages of animals and disease severity
OAisadiseaseofadults, andgrowinganimals, likechildren, seemto
have a better capacity at managing joint damage. Moreover, incontrolled experiments, the complexities of changing skeletal size and
metabolism during growth can obscure how joints respond to injury
and therapy. Thus, to obtain themostmeaningful insights into human
OA, it is essential to use skeletally mature animals whenever possible.
The followingminimum ageswere proposed for the different species:
In rats and mice, it is noteworthy that not all growth plates nor-
mally close completely. In rats and mice at the ages noted above,
longitudinal long bone growth has ceased, though the potential for
long bone growth still exists. In such species, scientists should be
mindful of treatments thatmight reactivate senescent growthplates.
Genetically modiﬁed mice should ordinarily be studied at 9e12
months when natural OA lesions start to appear in wild type mice.
In working with animals, we must remember the differences to
humans. For example, adult human articular cartilage has a cell
densityone tenthof that in adult rabbits andof intermediate value in
dogs. Yet the total number of cells beneath one squaremillimeter of
cartilage surface are remarkably similar between humans and
rabbits2. Hence, we need to be mindful of various tissue differences
between species.
Animal models of OA have a wide range of severity and rate of
progression of pathogenic changes. Naturally occurring models
(e.g., Dunkin-Hartley guinea pig, C57Bl6 mice) develop over a much
longerperiodof theanimal’s life. Somemodelsexhibit rapidandsevere
structural changes (e.g., multiple surgical injuries) that can be of value
whenexamining inhibitors of cartilagedegradation (e.g.,meniscal tear
model in guinea pigs). Regardless of the rate of development of
pathology, it is important to study selected sites of the joint (e.g., areas
of abnormal loadings/extremeoverload) rather than thewhole joint to
ensure valid comparisons can be made to test speciﬁc hypotheses.
For a variety of reasons, it is advantageous for industry to use
more rapid models of OA for drug development. This approach may
not be asking too much of the treatment since models of rapid
onset inﬂammation and joint destruction for inﬂammatory arthritis
(e.g., collagen induced arthritis) have proven of value in disease-
modifying drug development for inﬂammatory arthritis. This
should be remembered in OA. In contrast, a slower developing OA
model, more like human OA, may afford greater opportunities to
control joint damage with a less potent drug.
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There is a perceived advantage in using naturally occurring
models of OA (e.g., Dunkin-Hartley guinea pig) in that they are
more like human OA with slower onset and progression. Yet, like
human OA, these models are not necessarily more sensitive when
trying to identify the initiating events. Hence, the basis for the joint
pathology and the disease onset need to be determined. Some
therapeutic compounds may produce better results in surgically
induced OA and have no effect on natural OA. Or it may be the
reverse. Both possibilities need to be considered. The spontaneous
model provides a proof of concept for certain classes of compounds
or therapies. For example, aging guinea pigs may be more appro-
priate than a young injured rabbit for testing a pro-anabolic ther-
apeutic agent. The availability of natural models is, however,
sometimes a limitation. Guinea pigs are large enough to use MRI
imaging and have been used successfully to examine MMP inhibi-
tors employing single site histological analyses in group sizes of
11e16 animals3.Chemically induced OA models involving iodoacetate
Intra-articular injection of iodoacetate creates an acute model
for the study of acute cartilage degradation and joint pain.
However, it has limitations as a model for OA. For example, since
iodoacetate is a metabolic poison, chondrocyte cell death in this
model is extensive, unlike in human OA. It does, however, provide
an in vivo model of rapid cartilage degradation mirroring some of
the events observed in in vitro organ culture screening studies4. The
model needs clinical validation (rapidly progressive OA? environ-
mental toxicology Kashin-Beck? iatrogenic arthropathy?).Mouse models
These may be of special use in the prevention of OA. There is
a need to use knock-out or transgenic mice to examine genetic
predispositions/contributions to OA. Conditional genetic manipu-
lations should be preferred, particularly those that can be induced
in adult animals. The relationship between disease and activity
impairment and OA onset requires more study. Remember that
genetically altered mice might better be considered as research
tools and are not necessarily better OA models. Natural onset OA is
clearly more pronounced in the STR/ort and STR/1N mouse strains
and these are viewed as effective screening models. However, it is
important to recall that the exacerbating effect of joint loading in
human OA may not be accurately captured (due to scaling effects)
in mouse models.Drug targets and animal models
As indicated earlier, drugs to address the human condition
should be tested in adult animals where the disease is established.
Remember that the end point that is usedmay not always resemble
human OA. The molecular target of the drug should be considered
when selecting one model over another. More than one model will
probably be needed to identify and substantiate the potential
therapeutic efﬁcacy. Do not limit studies to only one model.
Genetically modiﬁed mice may be particularly useful since the
genetic change(s) is largely known and ﬁtted to the drug target.Analyses of animal models
Assessment of structural change
Cartilage offers us an opportunity to detect early change. The
importance of measuring and preventing macroscopic changes in
articular cartilage structurewas clearly recognized since the ultimate
goal is to prevent such changes. But at present we are unsure of the
relative importance of macroscopic vs microscopic changes when
assessing drug effects. This is because macroscopic changes in carti-
lages only reﬂect more surface related events. Histology and/or
imaging are also required. But if change starts superﬁcially in carti-
lage, as many human studies indicate, macroscopic measures may
sufﬁce. Histological change must be monitored when there is little
evidence of structural change. It is necessary to establish a hierarchy
of change to measure e what is the minimum that needs to be
measured and what are the structural features we should focus on.
Therewas some consensus that thewhole-joint cartilage need not be
assessed: speciﬁc sites should be monitored, such as where joint
loading changes and where more severe and less severe lesions are
commonly found in a given model. In early human OA, the changes
are more prevalent in some parts of the joint than in others. While
changesoftenoccur throughout the joint, there are sentinel signs that
anticipate the overall pathology of the joint.
Wemust deﬁne and standardize macroscopic changes since this
is presently lacking in animal models. Recently, a consensus was
reached for scoring human OA macroscopically5 and we need to
deﬁne what we should measure and how this should be done in
animal models, recognizing the practical differences in assessing
small vs large animals.
For a given model (e.g., surgical, chemical, or natural) different
species should be compared. There is a desire to identify the most
sensitive, speciﬁc, fastest and cheapest models and measures.
Noninvasive imaging byMRI andmicroCT6 using cartilage contrast in
CTneeds to be tailored to a givenmodel and validated. A best practice
of macroscopic assessment of cartilage change is required. Ideally, it
will be possible to eventually substitute less invasive technologies for
the gold standard of macroscopic and microscopic evaluation.
In terms of a standard histologic grading system we should use
one that is similar to that used for human studies. There is a need to
deﬁne the histological changes observed so that all researchers use
the same terminology and mean the same thing. This will facilitate
comparisons between results. The Mankin scoring system is of
value, but has many limitations e particularly in early OA. Since
structural changes in cartilages are similar among species, it would
be ideal if the same measurements can be used for all models. At
present there is no consensus on a common grading system. But it
is agreed that it should include synovial changes as well as changes
in cartilage structure, composition and cells. We are unsure of what
to measure histologically in bone e this requires deﬁnition. It is
essential to deﬁne a common grading system for each of the
features shared between human OA and models of OA.
Therewas agreement that changes in cartilage,menisci, bone and
synovium should all be assessed. The recognition of bone bruises by
MRI in humans and animals is a good example of how new tech-
nology improves our understanding of how tissues, other than
articular cartilage, respond to joint injury. Synovial and bone changes
may help improve our understanding of how the whole joint may
contribute to OA symptomatology. Sampling techniques, whether for
imaging or histopathology, must also be standardized to ensure we
are comparing apples with apples. It is important to remember that
the scoring system and evaluation outcomes invariably depend on
the questions that are being asked and the drug targets being sought.
Similarly, the characterization of the microscopic anatomy of
joint tissues (e.g., histological preparation, tissue sampling sites,
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reproducible staining, staining intensity and chromaticity and
hence reproducible grading (e.g., metachromasia as an index of
proteoglycan concentration). There was a consensus that it is
desirable to introduce histomorphometric measurements of carti-
lage and bone changes (e.g., by quantitative digital image analysis
and stereology), to achieve better standardization and to ensure
unbiased evaluation.
There was no consensus whether osteophytes should be
included in the assessment of osteoarthritis, as in human studies
(e.g., Kellgren/Lawrence grading on X-ray), as they are of uncertain
signiﬁcance. Yet, osteophytes are a hallmark of human osteo-
arthritis.. If osteophytes are to be assessed, their presence, loca-
tion, and extent should be noted; if they are to be quantiﬁed, then
a volumetric or planimetric record should be made. Whether bone
or cartilage changes of osteoarthritis are ﬁrst observed in animal
models is unclear, though the formation of the marginal osteo-
phytes in OA begins at the chondrosynovial junction and is likely
controlled primarily by a combination of mechanical and
biochemical factors7.
Current imaging technologies clearly have an important role to
play in assessing early lesions in experimental OA. As more speciﬁc
and sensitive imaging protocols and contrast agents are developed,
the easier itwill be to study thepathogenesis ofOA longitudinally. It is
likely that a sensitivemetric for treatment efﬁcacywill be altering the
trajectory of the natural history of whole-joint changes in OA.
Assessment of pain
The control of OA pain and fatigue is viewed by patients/
consumers as the greatest unmet need in this condition (Canadian
Arthritis Network and Institute for Musculoskeletal Health and
Arthritis, Canadian Institutes of Health Research jointly sponsored
OAConsensus Conference, Toronto, 2002). It is therefore imperative
that new models (in vitro and in vivo) be developed that enable the
objective testing of OA symptoms. Over the past several decades,
substantial advances have been made in objectively assessing
distress in animals. Suchmethods can be employed as surrogates of
human pain, discomfort, and fatigue. Moreover, such models need
to be combined in studies with new drugs that can better control
joint pain, whether or not they have structure- or disease-modi-
fying activities. In humans there is evidence of an association
between structural joint damage and joint symptoms8 contrary to
some earlier reports. It is unclear whether pain is linked to disease
initiation or progression. There was a consensus that a fuller
understanding of OA pain in humans was needed so that the
appropriate animal models could be developed to enable the
assessment of OA symptoms in preclinical studies.
In human OA we also need to determine:
 Whether pain status and mechanisms change over time. Can
they be modeled in animals?
 Do pain conditions show the same pharmacology over time?
 We must determine whether different pain mechanisms are
operative in a patient at different times.
We must clarify the clinical measures of pain and tenderness in
a manner similar to a functional WOMAC (Western Ontario and
McMaster Universities Osteoarthritis Index) analysis.
Animal models for the study of pain: recommendations
In an animal model, it is important to include multiple time
points when assessing pain. For the study of pain, mechanisms and
pharmacological interventions to treat pain may change over timein models. Some participants felt that naturally occurring models
may better represent pain than surgically induced models. Yet it
was felt that in view of the early involvement of meniscal damage
in idiopathic OA, and the presence of nerve endings in the
peripheral portion of themensicus, meniscus-basedmodels may be
particularly relevant to studies of OA pain. Chronic OA has a large
component of microinjury and surgical models may therefore
represent this. Instability in idiopathic OA is similar, though not
necessarily identical, to surgical instability. Overall, surgical models
were considered relevant and acceptable for pain measurement,
though sham surgery is mandated to control for the possible effects
of iatrogenic neurectomy.
There was agreement that the intra-articular monoidoacetate
model does not produce the typical pathology of human OA, but is
a clinically relevant model of arthritis pain. Iodoacetate is an
example of how the mode of action of a compound can inﬂuence
the choice of outcome measures in a particular animal model.
To best study pain in OA, there should be a close collaboration
between pain and OA researchers.
The measurement of pain
There was agreement that scientists’ need suitable standardized
testing procedures to detect and document “total” animal noci-
ceptive behaviour. We need to develop methods to assess animal
behaviour that reﬂects pain, joint instability, and function. A hier-
archical approach to assessment is needed.
Functional gait analysis may be inﬂuenced by pain and, there-
fore, could be used as a surrogate pain measure. It should also be
noted, however, that it may be difﬁcult to interpret kinematic
measures in instability models since changes may be related to an
alteration in joint function rather than due to musculoskeletal pain
per se. Intra-articular anesthetic challenge might be one strategy to
decouple gait mechanics from pain physiology.
It was noted that spontaneous pain behaviour is different from
evokedpainbehaviour. Both shouldbemeasuredover timeandused
in testingpotential therapeutic agents. Since patients have a difﬁcult
time distinguishing pain and function, this may be similar in animal
models. The emotional component of pain should be measured
using a behavioural output. Neuropathic pain has standardized
clinical tests, but OA pain does not. Quantiﬁed sensory tests for OA
should be developed and used in clinical and preclinical studies.
Since pain has different manifestations (stabbing, throbbing, sear-
ing, burning, overall, general, etc.) we should try andmeasure these
objectively in animals, possibly electrophysiologically.
It is essential that the research community identify what is
a clinically signiﬁcant reduction inpain in animals for the guidance of
researchers and regulatory agencies.
In conclusion, we need gait analyses, electrophysiological and
behavioural tests to distinguish evoked pain from spontaneous pain.
Gene expression vs biochemical analyses in assessing joint
injury and repair
Besides humans, complete genomic analyses are now available
in mice, rats and dogs and will be available soon for an increasing
number of species. In any analysis of joint tissues in OA, we should
examine the balance between matrix synthesis and degradation
and identify any alterations in the regulation of these molecules
since these changes occur in human OA. We should be analyzing
menisci, ligaments, periarticular tendons, synovia, capsules and
subchondral bone, as well as articular cartilage e because OA is
a condition involving and affecting all these tissues.
In the study of joint tissues, gene expression analysis results
should be questioned as to their value: they sometimes only
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Biochemical analyses can detect and measure functional products
of gene expression that are responsible for structural and compo-
sitional changes. Gene expression can be viewed as what the cells
are thinking about in the short term; changes in matrix proteins
and carbohydrates are the more long-term changes in the
biochemical and mechanical milieu. It is noteworthy that the
turnover of some structural macromolecules in the extracellular
matrix may take many months or even years. So the presence of
a molecule in the matrix does indicate whether it was synthesized
at birth or made yesterday unless this can be demonstrated. Hence,
molecular markers of newly formed or newly degraded matrix
molecules are highly valuable. So too are changes in the gene or
protein expression of molecules that inﬂuence tissuemetabolism in
joint injury, repair and degeneration and which are associated with
phenotypic changes in cells such as chondrocyte hypertrophy and
its association with collagen cleavage9.
Functional repair and degradative processes should be identi-
ﬁed and recorded rather than non-functional processes. Be aware of
the lack of intrinsic repair capacity in adult articular cartilage. Gene
expression analyses in the dorsal root ganglion and spinal cord in
animal models may prove of value in studying pain in both spon-
taneous and surgical models. Unlike connective tissues, tissues of
the nervous system have rapid turnover of proteins, so protein
biochemistry and immunochemistry of nerves is an important and
informative indication of recent nerve activity. Researchers should
remember that OA models at present represent models of damage
rather than repair. For example, the elevated expression of struc-
tural macromolecules can be viewed as anabolic, yet, since catab-
olism is also elevated, the reality is a state of high turnover.
In summary, the focus should, wherever possible, be on func-
tional products and their balance reﬂecting degradation, repair,
disease onset and progression.
The use of biochemical biomarkers to predict OA progression
In animal studies, biochemical/molecular markers in body ﬂuids
are viewed as useful indicators for studying tissue dynamics, in
particular cartilage and bone turnover and synovitis. But they need
to be complemented with imaging and histology over multiple
time points to assess their predictive value and determine rela-
tionships to disease onset and progression.
We should distinguish diagnostic biomarkers (which may be
qualitative) from those predictive of disease progression or
response to treatment (that need to be quantiﬁed). Again, the time
at which a given biomarker may be of most value probably depends
on the time point at which it is used to predict progression (see
above for discussion on how altering the trajectory of natural
history of OA may be a useful tool for establishing efﬁcacy).
Biochemical markers should be classiﬁed: a classiﬁcation
system has been proposed10.
Biomarkers are needed to identify disease activity prior to
radiographic change as revealed byMRI, DEXA or other radiological
methods. The use of skeletally immature animals in OA models is
not only inappropriate due to the demographics of OA, but also
confounds biochemical marker analyses since biomarkers can be
elevated during growth (increased matrix turnover/remodeling)
and we may be evaluating growth more than identifying the
pathological changes in OA.
We should be assessing both anabolic and catabolic markers and
those of synovitis to determine imbalances in preclinical OAmodels
(as reﬂected above) and not a single biomarker. Thus, a combina-
tion of changes in biomarkers (e.g., balance of cartilage type II
collagen synthesis vs degradation) may well be more predictive
than a change in any one biomarker. It is essential that assays bestandardized to enable comparisons of results. Normal values and
standard deviations are required for comparison. The threshold for
a signiﬁcant biochemical marker change should be identiﬁed as
should changes thereof that are products of pathology. Biomarker
changes should be related to behavioural outcomes to explore the
possible interrelationships between pathology and pain.
Biomarkers of pain (hyperalgesia and allodynia) should be identi-
ﬁed and measured.
The assessment of synovial and capsular changes and inﬂammation
in models of OA
Although OA is not considered an inﬂammatory arthritis
(like RA), it is not a non-inﬂammatory process. Indeed, classic
inﬂammatory changes clearly occur in the synovium and capsule
and a variety of inﬂammatory changes (such as upregulation of
proinﬂammatory cytokines) involve other connective tissues
including cartilage and bone. Blood ﬂow in a joint is conﬁned
mainly to the bone, synovium and capsule. It is an index of
inﬂammation since it involves angiogenesis, vasomotor tone, and
changes in vascular/endothelial cell permeability. These parame-
ters should be measured in OA models. Thermography and early
phase scintigraphy are valuable methods to measure blood ﬂow.
Laser Doppler measurements can detect the hyperaemia of
inﬂammation. The biochemical biomarker hyaluronic acid (hya-
luronan) generated by synovial cells is increased in serum in
synovitis and this can be measured.
It is important to determine how joint innervation and peripheral
neuropeptidesmay change in OAmodels in associationwith synovitis.
Ultrasound and MRI and early phase scintigraphy are used in
human studies to detect synovitis and may be of value in animal
studies too.
Biomechanical analyses of joint tissues
The biomechanical properties of joint tissues are measures of
what is most important e the functional properties of a tissue e
and should therefore bemonitored in OAmodels both in vivo and ex
vivo. These measurements should include cartilage compressive
stiffness and elasticity and their time-dependant changes. The
natural variation of biomechanical properties of cartilage with age
and joint site (condyle vs tibial plateaus) needs to be distinguished
from pathological changes by carefully controlled testing of
comparable carefully deﬁned regions. The mechanical strength of
the cartilage may be a ﬁnal common denominator with respect to
these measures. The mechanical properties of the subchondral
bone, menisci, ligaments and the capsule also need assessment.
Correlations should be made with structural and biochemical
properties and symptoms. Determinations of whether biome-
chanical properties are related to joint movement are required. The
effect of load on a diseased tissue needs to be understood.
New biophysical techniques to measure cartilage functional
quality such as in vivo arthroscopic determination of streaming
potentials could be applied to OA models in larger species.
Clearly there is a need for an integrated approach to the
assessment of joint damage; a given drug may only inﬂuence one
important parameter.
Other general assessments and recommendations for overall
strategic analyses
In modeling the process and end points of human OA, we should
also assess symptoms such as lameness (gait analysis), joint loading
(incapacitance) and range of motion together with pain,
nocifensive behaviour (hyperalgesia/allodynia), evoked vs
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temperature.
Tissues comprising the whole joint should be structurally
assessed using imaging, macroscopic assessment, histopathologic
assessment at deﬁned sites of change (with histomorphometric
methods), biochemistry, molecular biology/gene expression,
physiological and biomechanical properties of joint tissues as well
as joint function, (kinetics, kinematics, stability).
Methods used in both human and animal studies need to be stan-
dardized to permit the evaluation of change in both situations so that
meaningful comparisons can be made. Change must be quantiﬁed to
permit parametric statistical change to be identiﬁed. End points must
be deﬁned and meaningful (either individual or composite).
Essential safety issues in animal models of OA
In dealing with pharmaceutical therapies, we must examine the
toxicology related to the route of delivery and include the muscu-
loskeletal system in these analyses. We must analyze the phar-
macogenetics and pharmacodynamics (catabolism and anabolism)
as well as the pharmacokinetics.
In systemic treatment, especially for molecular targets of joint
health, we should study in normal animals the effects of drugs on
the structure and biochemical composition of the musculoskeletal
system including joints. For intra-articular delivery, speciﬁc toxi-
cological concerns are reduced but must still be addressed, espe-
cially for local tolerability.
Reminders
Structure/function/symptom interrelationships
These should be explored and included in OA modeling.
Wherever possible, we should pay careful attention to the time
course of disease, when symptoms develop and when symptom
modiﬁcation with therapy may occur. We must examine the
biomechanical properties and geometry of joints so that we can
better understand joint function and changes thereof in relation-
ship to structure and symptoms. Such integrated studies are sorely
needed. They may help to determine whether the treatment of
symptoms can improve function.
Treatment of experimental OA: prophylaxis, progression, reversal
It is important to recognize different treatment options that
address prophylaxis (pretreatment), slowing of progression (early
treatment) and reversal. Phasic treatment and crossover studies
should be addressed in the experimental design. Attention to
activity and diet should be included as part of the treatment
protocol. Both anti-catabolic and pro-anabolic options are available.
Early treatment is considered to produce the greatest opportunity
for success in both experimental and human studies based upon
our experience with rheumatoid arthritis.
Markers of disease onset, activity and progression
It is important to identify and use indicators of risk, onset,
activity and progression, which may include genomic/metab-
olomic, biochemical, genotype/phenotype and imaging markers.
These offer insights in vivo that may pinpoint changes in progres-
sion that then predict structural or symptomatic or functional
alterations. It is important to remember that biochemical markers
of skeletal turnover usually identify process whereas imaging
markers tend to recognize outcome. New spectroscopic imagingtechniques may be developed sufﬁciently to enable the identiﬁca-
tion of both process and outcome.
What can the Canadian Arthritis Network, OARSI and others
do to help?
They can offer a forum for the exchange and dissemination of
knowledge with various stakeholders, including patients. This
addresses self-education, training, and the promotion of trans-
disciplinary approaches. The importance of negative results needs
to be addressed. Access to this information is important. The
coherence of methodologies between preclinical and clinical
studies should be promoted, as well as knowledge exchange among
stakeholders, including researchers, practitioners, industry,
government, regulatory agencies and patients.
CAN could act as amuch-needed knowledge and data repository
(for negative as well as positive data) using a protected website for
information storage and dissemination, providing a forum to
enable consensus building and discussion of research issues related
to preclinical OA, as part of its overall initiative in OA.
Concluding remarks
It is important to remember that some models can mimic
aspects of the human disease, but no single animal model is able to
mirror all variants and aspects of human OA. There was some
consensus that we should treat and model subsets of OA such as
inﬂammatory OA.
Therearedifferent subsets of animalmodels, as inhumanOA.There
areprimary idiopathicmodelsofnatural, age-relateddiseaseonset and
secondary experimentally induced disease. Secondary models of OA
include: surgical instability, chemical, and impact models.
There is the natural occurrence of OA in veterinary patients, be it
because of aging, trauma or genetic causes.
The best model on face value, in terms of natural occurrence and
animal size permitting multiple assessments of the kind used in
humans, is spontaneous OA in the Dunkin-Hartley guinea pig,
though the inﬂuence of body mass and obesity are complications
yet to be resolved.
There was a general consensus that, ultimately, less severe models
are required tobetterevaluatepotential therapies foruse inhumanOA.
In primary models we need to examine whether we can model
risk factors for OA, namely diet (obesity), genetics, activity, age,
gender, stress and joint loading. These variables should be
considered with the design and outcome of all models of OA onset
and intervention.
Our goal has been to reach some consensus on the appropriate
use of animal models for the detection, study and treatment of OA.
We have made progress towards this goal although much remains
to be done. We also need to further enhance the existing high
standards of the three “Rs” in animal experimentation, namely:
1. Reduce e use fewer animals;
2. Reﬁne e enhance efﬁciency of the experimental protocol; and,
3. Replace e employ in vitro over in vivo whenever possible.
We recognize that adequate severity of disease is achieved in
existing models. But there should be awareness that overly severe
experimental models can be counter-productive in presenting us
with greater challenges than we meet in human disease. The
reduction of disease by experimental intervention needs clear
deﬁnition so that severity and responses to treatment can be better
deﬁned, standardized and compared. The use of standardized
experimental methods and different joint tissues to identify
changes in joint signs, symptoms, structure, turnover and function
R. Poole et al. / Osteoarthritis and Cartilage 18 (2010) S10eS16S16should be maximized to obtain more comprehensive and more
meaningful information of relevance to the human disease. We
should be aware that in some surgical models, the contra-lateral
joint can represent a model of less severe and more slowly
progressive degenerative change modeling human OA. Remember
that the literature contains validated studies of animal models e
they should be carefully noted.
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